ECO 2026: tirzepatide shows potential for T1D treatment
GLP-1 agonists have had a dramatic surge in popularity in recent years as a treatment for obesity and type 2 diabetes (T2D).
Therapy Area
ECO 2026: gut hormone signals differ in T1D with obesity
ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition
Early detection of bowel Cancer in the UK represents success of screening program
AAN 2026: Tavapadon post-hoc analysis strengthens its D1/D5 agonist pitch
AAN 2026: Head-to-head trial shows superiority of Qulipta for migraine prevention
Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
ESCMID Global 2026: Zelicapavir demonstrates benefits for high-risk adults with RSV
